Nakamura Tsuneya, Nakamura Shigeo, Yokoi Takio, Suzuki Hiroko, Ohashi Kazuhiko, Seto Masao
Department of Gastroenterology, Aichi Cancer Center Hospital, Chikusa-ku, Nagoya 464-8681.
Jpn J Cancer Res. 2002 Jun;93(6):677-84. doi: 10.1111/j.1349-7006.2002.tb01306.x.
Little is known about the clinicopathological differences between API2-MALT1 chimeric transcript-positive and -negative gastric low-grade B-cell lymphomas of mucosa-associated lymphoid tissue (MALT) type. The aim of this study was to clarify those differences in gastric MALT lymphoma. Twenty-three patients with gastric MALT lymphoma were enrolled in a unicenter study. Helicobacter pylori (H. pylori) infection status and clinical stages were investigated. Antibacterial treatment was performed for every patient. Responsiveness of MALT lymphoma to this treatment was assessed by means of regular follow-up endoscopy combined with biopsy. All cases were examined for API2-MALT1 chimeric transcript by means of RT-PCR and sequencing analyses. H. pylori infection status was assessed as positive in 20 patients and negative in three. With regard to responsiveness to antibacterial treatment, complete remission was observed in two patients, partial remission in 12 and no change in nine. API2-MALT1 chimeric transcript was detected in seven patients, all of whom showed no change in response to antibacterial treatment. API2-MALT1 positivity was found to be significantly correlated with responsiveness to antibacterial treatment (P = 0.0001), absence of H. pylori infection (P = 0.0198), and gross cobblestone mucosa observed endoscopically (P = 0.0198). For the other factors (age, sex, dominant site of lesion, high-grade component, infiltrated layer of gastric wall, nodal involvement or clinical stages), there were no differences between API2-MALT1 chimeric transcript-positive and -negative cases. Gastric API2-MALT1 chimeric transcript-positive MALT lymphoma generally features unresponsiveness to antibacterial treatment, and is thought to be unrelated to H. pylori infection in its pathogenesis. Our findings indicate the presence of different clinical subtypes in gastric MALT lymphomas.
关于伴有API2-MALT1嵌合转录本阳性和阴性的胃黏膜相关淋巴组织(MALT)型低度B细胞淋巴瘤的临床病理差异,目前所知甚少。本研究的目的是阐明胃MALT淋巴瘤的这些差异。23例胃MALT淋巴瘤患者纳入一项单中心研究。调查幽门螺杆菌(H. pylori)感染状况和临床分期。对每位患者进行抗菌治疗。通过定期随访内镜检查结合活检评估MALT淋巴瘤对该治疗的反应性。所有病例均通过RT-PCR和测序分析检测API2-MALT1嵌合转录本。H. pylori感染状况评估为20例患者阳性,3例患者阴性。关于对抗菌治疗的反应性,2例患者完全缓解,12例部分缓解,9例无变化。7例患者检测到API2-MALT1嵌合转录本,所有这些患者对抗菌治疗均无反应变化。发现API2-MALT1阳性与对抗菌治疗的反应性(P = 0.0001)、无H. pylori感染(P = 0.0198)以及内镜观察到的粗大鹅卵石样黏膜(P = 0.0198)显著相关。对于其他因素(年龄、性别、病变优势部位、高级别成分、胃壁浸润层、淋巴结受累或临床分期),API2-MALT1嵌合转录本阳性和阴性病例之间没有差异。胃API2-MALT1嵌合转录本阳性的MALT淋巴瘤通常对抗菌治疗无反应,并且在其发病机制中被认为与H. pylori感染无关。我们的研究结果表明胃MALT淋巴瘤存在不同的临床亚型。